Join to View Full Profile
Division of Hematology and Medical Oncology3181 SW Sam Jackson Park Road, OC14HOPortland, OR 97239
Phone+1 503-494-8534
Dr. Roeland is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Eric Roeland, MD, FAAHPM, FASCO, is an Associate Professor at the Oregon Health and Science University. He is a medical oncologist and palliative care specialist whose clinical practice focuses on caring for adults with cancer experiencing poorly controlled symptoms. As the Director of the Knight Cancer Institute Symptom Science Clinical Research Program, his research focuses on Symptom Science, characterizing symptoms' phenotypes and biological underpinnings to develop effective novel clinical interventions to inform clinical practice. He has participated in many industry- and grant-sponsored clinical trials spanning the last decade and has first-hand experience conducting supportive oncology clinical trials.
Education & Training
University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Scripps Mercy HospitalFellowship, Hospice and Palliative Medicine, 2008 - 2009- University of California (San Diego) Medical CenterResidency, Internal Medicine, 2005 - 2008
University of Colorado School of Medicine Anschutz Medical CampusClass of 2005
Certifications & Licensure
CA State Medical License 2007 - Present
OR State Medical License 2021 - 2025
WA State Medical License 2023 - 2025
MA State Medical License 2018 - 2022
American Board of Internal Medicine Hospice and Palliative Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15 Start of enrollment: 2022 Nov 21
- Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy Start of enrollment: 2020 Oct 07
- A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer Start of enrollment: 2011 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates.Yeon Hee Park, Giampaolo Bianchini, Javier Cortés, Luca Licata, María Vidal
Future Oncology. 2025-04-01 - Comparison of Risk Prediction Models to Estimate Opioid-Induced Respiratory Depression, Oversedation, and Overdose in Patients with Cancer.Norint P Tung, Parker K Kaleo, Eric J Roeland, Joseph D Ma
Journal of Pain & Palliative Care Pharmacotherapy. 2025-03-20 - Opioid conversion in adults with cancer: MASCC-ASCO-AAHPM-HPNA-NICSO guideline.Mellar P Davis, Andrew Davies, Mary Lynn McPherson, Akhila S Reddy, Judith A Paice
Supportive Care in Cancer. 2025-03-03
Press Mentions
Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)December 12th, 2024- Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)November 4th, 2024
- Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)November 4th, 2024
- Join now to see all
Professional Memberships
- Fellow
- Fellow
- Multinational Association of Supportive Care in CancerMember
Other Languages
- Spanish
External Links
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
